S-(+)-Clopidogrel Hydrogen Sulfate (CAS 120202-66-6)

S-(+)-Clopidogrel hydrogen sulfate, an enantiomer of clopidogrel, is a potent and selective inhibitor of adenosine diphosphate (ADP) receptor on platelet cell membranes. This compound functions by irreversibly modifying the P2Y12 component of ADP receptors, thus inhibiting platelet aggregation. Its unique mechanism involves the hepatic cytochrome P450 system, where it is metabolized to an active thiol metabolite that binds covalently to the P2Y12 receptor, leading to a sustained inhibition of platelet activation and aggregation. This attribute makes it a focal point in research studies investigating the pathways of platelet aggregation and the development of antiplatelet agents. Specifically, its role in the elucidation of the ADP receptor signaling mechanism and the interplay between genetic polymorphisms in the cytochrome P450 system with drug efficacy has been a subject of extensive study. Moreover, S-(+)-clopidogrel hydrogen sulfate′s enantiomeric specificity highlights the significance of stereochemistry in the pharmacodynamic properties of drugs, guiding research towards the development of more selective and efficient therapeutic agents in areas beyond its traditional applications, strictly focusing on its biochemical and molecular interactions.